Skip to main content
Watch Insiders
OCULHealthcare

Ocular Therapeutix Inc (OCUL) Insider Trading

In the last 90 days, 6 Ocular Therapeutix Inc (OCUL) insiders reported no open-market purchases and 8 sales totaling $567,500. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Oct 8, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Oct 8, 2026Todd AndermanChief Legal OfficerSale11,984$7.29$87,363
Oct 2, 2026Peter KaiserChief Development OfficerSale9,990$7.05$70,430
Oct 2, 2026Jeffrey S. HeierChief Scientific OfficerSale10,869$7.05$76,626
Aug 31, 2026Donald NotmanChief Operating OfficerSale1,099$10.24$11,254
Aug 24, 2026Peter KaiserChief Development OfficerSale3,035$10.77$32,687
Aug 24, 2026Sanjay NayakChief Strategy OfficerSale1,897$10.78$20,450
Aug 24, 2026Jeffrey S. HeierChief Scientific OfficerSale3,296$10.78$35,531
Aug 24, 2026Pravin DugelSee RemarksSale21,649$10.77$233,160
Jun 3, 2026Nadia WaheedChief Medical OfficerSale14,828$8.27$122,628
May 26, 2026Pravin DugelSee RemarksSale21,156$8.20$173,479
🔒 Create Free Insider Alerts — Join Watch Insiders

Common questions

OCUL insider trading FAQ

Are OCUL insiders buying or selling?
Over the last 90 days, OCUL insiders were net sellers, reporting $0.00 of open-market purchases and $567,500 of sales.
When was the last OCUL insider purchase?
No open-market insider purchase of Ocular Therapeutix Inc stock was reported in the last 90 days.
Where does OCUL insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Ocular Therapeutix Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.